Skip to main content
OpenTrials
Completed

NCT Number: NCT07700082

HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC

This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three Chinese medical centers and the public TCGA-LIHC database. We developed a multimodal hybrid deep learning prognostic model (named HCC-MPDS) integrating multi-source medical data to stratify HCC patients into high-risk and low-risk recurrence groups after surgery. The primary goal of this study is to compare postoperative recurrence-free survival (RFS) and overall survival (OS) between the two risk subgroups, and evaluate whether this artificial intelligence prediction system can help clinicians identify patients who may benefit from postoperative adjuvant therapy. No new experimental drugs or interventional treatments were provided to participants; all data were retrospectively extracted from archived medical records under institutional ethics approval, with waived written informed consent for de-identified historical samples and images.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, 230000, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with pathologically confirmed hepatocellular carcinoma (HCC);
  • patients accepting curative surgical resection (SR) without preoperative adjuvant treatment;
  • MRI were performed two weeks before surgery.

Exclusion criteria

  • incomplete clinical information;
  • incomplete or suboptimal quality of preoperative MRI imaging data;
  • unavailable or poor-quality pathological whole slide images (WSIs);
  • incomplete follow-up data.

Treatment and study plan

Primary outcomes

  1. Recurrence-Free Survival (RFS)

    Time frame: Up to 60 months after hepatectomy

    Time from surgical resection to first local/regional recurrence, distant metastasis or all-cause death, whichever occurs first

Sponsors and collaborators

Lead sponsor

Anhui Provincial Hospital

Other Gov

Registry information

Official study title

Multimodal Hybrid Deep Learning-based Prognostic Decision System to Guide Adjuvant Therapy in Hepatocellular Carcinoma After Surgical Resection

Acronym: HCC-MPDS

Important dates

Study start
2020
Primary completion
2024
Study completion
2026
First posted
Jul 13, 2026
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.